Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year. The post Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to…

Read More

Ben Salter, SafeRide Health

Ben Salter is the Chief Product Officer of SafeRide Health. They are one of the biggest players in non-emergency medical transport (NEMT) working predominantly for health plans that have Medicaid or Medicare Advantage members. Getting people to their appointments is a big deal–think disabled or sick people who will miss clinical appointments if they can’t…

Read More

The Missing Piece: Tech and Mental Health

By involving highly experienced therapists and mental health administration experts from the beginning of development of new tech, we not only build tools that are more effective, but also build trust and confidence among clinicians. The post The Missing Piece: Tech and Mental Health appeared first on MedCity News.

Read More